Haematologica, Vol 93, Issue 2, 317-318 doi:10.3324/haematol.11680
Copyright © 2008 by Ferrata Storti Foundation
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Franceschino, A.
Right arrow Articles by Gambacorti-Passerini, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Franceschino, A.
Right arrow Articles by Gambacorti-Passerini, C.

Chronic Myeloid Leukemia

Alterations in creatine kinase, phosphate and lipid values in patients with chronic myeloid leukemia during treatment with imatinib

Anna Franceschino1, Lucia Tornaghi1, Valerie Benemacher2, Sarit Assouline2, Carlo Gambacorti-Passerini1,2,

1 University of Milano Bicocca, Monza, Italy; San Gerardo Hospital, Monza, Italy;
2 Department of Oncology, McGill University, Jewish General Hospital, Montreal, Quebec, Canada. Key words: CML, tyrosine kinase inhibitor, long term side effects, CK Funding: AIRC, NCIC, AIFA, CARIPLO

Correspondence: Carlo Gambacorti-Passerini, Professor of Internal Medicine and Oncology/University of Milano Bicocca, Italy and JGH, McGill University, Montreal, Canada., E-mail: carlo.gambacorti{at}unimib.it

Imatinib, the treatment of choice for chronic myeloid leukemia, is generally well tolerated. We present here data from a retrospective analysis on metabolic abnormalities occurring during therapy which show increased creatine kinase, inverse creatine kinase-phosphate correlation, cholesterol and triglyceride values.